Bouquet (EP)

Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

Retrieved on: 
Wednesday, February 8, 2023
Proximity, EDC, Syneos Health, MD, Laika (EHR testing framework), Bouquet (EP), EHR, Cancer, Data management, Patient, Learning, Health information management, Quality control, Partnership, Clinical trial, Exercise, Medical imaging, Pharmaceutical industry

Through the partnership, Syneos Health will use the proXimity platform to automate sponsor data transfers from EHRs to EDCs for clinical trials, helping to accelerate the performance of new therapies for patients.

Key Points: 
  • Through the partnership, Syneos Health will use the proXimity platform to automate sponsor data transfers from EHRs to EDCs for clinical trials, helping to accelerate the performance of new therapies for patients.
  • This collaboration support’s the Company’s commitment to listening and learning from sites and adapting to meet their most critical needs.
  • By partnering with Equicare to use proXimity, we are further addressing challenges sites and sponsors face regarding data capture, timelines and quality control,” said Michael Henning, President, Clinical Delivery, Syneos Health.
  • The platform now serves as a key tool for clinical trial data management, as well as assists sponsors in gaining access to their data to accelerate cancer research.

Lieff Cabraser, Equal Justice Society, and Serna & Associates PLLC Announce Filing of Federal Injury Lawsuit in California Against L'Oreal, Softsheen, Dermoviva and Others for Cancer Allegedly Caused by Repeated Use of Hair Relaxer Products

Retrieved on: 
Tuesday, January 17, 2023
Legal, Professional Services, Dark, Olive, Disease, EWG, Cardiovascular disease, Toxicity, Hypertension, Environmental Working Group, Big Dark Love, Failure, Hunger, Pressure, Uterine cancer, Quality of life, Family, Safety, Just, Health, Social stigma, Fibroid, Marketing, Woman, Metastasis, Tubing (recreation), Diabetes, Cancer, Biophysical environment, Complaint, Bias, Bouquet (EP), Sale, Equal, Central District, Fraud, Advertising, Hair, L'Oréal, California Consumers Legal Remedies Act, Dabur, Distress, Insurance, Cosmetics, Birth control, Dietary supplement, Black, Plaintiff

In 2020, the global Black Hair care market was estimated at $2.5 billion, with the hair relaxer market alone estimated at $718 million in 2021.

Key Points: 
  • In 2020, the global Black Hair care market was estimated at $2.5 billion, with the hair relaxer market alone estimated at $718 million in 2021.
  • It is estimated that as many as 90% of Black women in the United States have used relaxer products.
  • This follows other studies which have raised concerns about the toxicity of ingredients in hair relaxers.
  • There was never any warning or labeling on the Products that normal use of the Products could cause her to develop cancer.

Raising awareness of endocrine disruptors among young people

Retrieved on: 
Wednesday, December 21, 2022
River, Human, Breast cancer, Toxicity, Cosmetics, Endocrine disruptor, Family, Lake, INRS, Laval, Toxicology, Communication, Cell, Student, Canada Research Chair in International Political Economy, Environment, Paper, Health, Faculty, Hormone, Issue, Bouquet (EP), Pollution, Parent, Interdisciplinarity, Science, Research, Ageing, Aquaculture, Sewage, Canning, Management, Pharmaceutical industry

Valérie Langlois and Isabelle Plante, professors at the Institut national de la recherche scientifique (INRS), have been studying endocrine disruptors for many years.

Key Points: 
  • Valérie Langlois and Isabelle Plante, professors at the Institut national de la recherche scientifique (INRS), have been studying endocrine disruptors for many years.
  • Through their work, they are striving to raise public awareness of the effects that these pollutants can have on the environment and human health.
  • For these two researchers, it is essential to make young people aware of the effects of contaminants.
  • Published in 2022, the first book entitled "Rainette Explores her Wetland – The Issue of Endocrine Disruptors Explained to Our Children'' , aimed at children aged 5 to 8.

Trace Femcare Announces Regenerative and Biodegradable Tampon, Aims to Disrupt the Period Care Category

Retrieved on: 
Tuesday, December 6, 2022
Woman, Carcinogen, Hygiene, Farmer, Bouquet (EP), TM, Carbon, Plastic, Marketing, Soil, Learning, Climate, Carhartt, Regeneration, Pesticide, Wefunder, Plague, Crunk, Agriculture, Trace, C4

A first of its kind, Trace Tampons are a petroleum-free alternative that actively sequesters carbon, addressing plastic pollution and global warming, two critical challenges that plague the disposable period care industry.

Key Points: 
  • A first of its kind, Trace Tampons are a petroleum-free alternative that actively sequesters carbon, addressing plastic pollution and global warming, two critical challenges that plague the disposable period care industry.
  • Claire Crunk, founder and CEO of Trace, is a women’s health nurse practitioner and mother of three daughters with a deep, personal connection to this endeavor.
  • Upon learning about ingredients like “dioxins and furans” (known carcinogens and endocrine disruptors) commonly found inside essential period care products, she knew she had to lead the initiative to find a solution.
  • Trace has raised $700,000 in outside capital to date and is accepting $300,000 of additional investment in their current round.

Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data

Retrieved on: 
Wednesday, November 9, 2022
Transfer, Health information management, Debiopharm, Clinical professor, Software, Industry, Mayo Clinic, Adoption, Patient, Company, VC, ESourcing Capability Model, Technology, Government, Union, EHR, Software as a service, Clinical trial, Guest appearance, Efficiency, Bouquet (EP), Associate, Drug development, Partnership, EDC, Data collection, Laika (EHR testing framework), Research, CRO, R, Therapy, EPRO, Quality, Health, Map, CEO, Medical device, Pharmaceutical industry, Medical imaging, Maccabi, Amgen

BOSTON and LAUSANNE, Switzerland, Nov. 9, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and YonaLink, a clinical trial software provider, today announced having completed an initial funding round, raising $6 million, to scale global growth and expand YonaLink's EHR-to-EDC integration platform. Purpose-built to stream and map up-to-date patient data, in real time, YonaLink's SaaS solution exports patient data directly from a clinical site's EHR system and transfers it into clinical research electronic data capture (EDC) systems.

Key Points: 
  • Purpose-built to stream and map up-to-date patient data, in real time, YonaLink's SaaS solution exports patient data directly from a clinical site's EHR system and transfers it into clinical research electronic data capture (EDC) systems.
  • "YonaLink is bridging the gap between patient care and clinical research, providing the missing link in clinical trial data collection and validation with technology that securely provides true EHR-to-EDC connectivity, without disrupting existing clinical trial workflows," said Iddo Peleg, YonaLink's CEO and co-founder.
  • YonaLink's data streaming technology drills into one of the clear inefficiencies in drug development moving data from EHRs to EDCs.
  • YonaLink equips research teams with the ability to extract up-to-date patient data from an EHR and stream that data into a clinical trial electronic data capture (EDC) system in real time, reducing clinical trial timelines and costs.

Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data

Retrieved on: 
Wednesday, November 9, 2022
Transfer, Health information management, Debiopharm, Clinical professor, Software, Industry, Mayo Clinic, Adoption, Patient, Company, VC, ESourcing Capability Model, Technology, Government, Union, EHR, Software as a service, Clinical trial, Guest appearance, Efficiency, Bouquet (EP), Associate, Drug development, Partnership, EDC, Data collection, Laika (EHR testing framework), Research, CRO, R, Therapy, EPRO, Quality, Health, Map, CEO, Medical device, Pharmaceutical industry, Medical imaging, Maccabi, Amgen

BOSTON and LAUSANNE, Switzerland, Nov. 9, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and YonaLink, a clinical trial software provider, today announced having completed an initial funding round, raising $6 million, to scale global growth and expand YonaLink's EHR-to-EDC integration platform. Purpose-built to stream and map up-to-date patient data, in real time, YonaLink's SaaS solution exports patient data directly from a clinical site's EHR system and transfers it into clinical research electronic data capture (EDC) systems.

Key Points: 
  • Purpose-built to stream and map up-to-date patient data, in real time, YonaLink's SaaS solution exports patient data directly from a clinical site's EHR system and transfers it into clinical research electronic data capture (EDC) systems.
  • "YonaLink is bridging the gap between patient care and clinical research, providing the missing link in clinical trial data collection and validation with technology that securely provides true EHR-to-EDC connectivity, without disrupting existing clinical trial workflows," said Iddo Peleg, YonaLink's CEO and co-founder.
  • YonaLink's data streaming technology drills into one of the clear inefficiencies in drug development moving data from EHRs to EDCs.
  • YonaLink equips research teams with the ability to extract up-to-date patient data from an EHR and stream that data into a clinical trial electronic data capture (EDC) system in real time, reducing clinical trial timelines and costs.

YonaLink Raises $6M in Funding to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data

Retrieved on: 
Tuesday, November 8, 2022
Technology, Research, Clinical Trials, Software, Biotechnology, Health, Pharmaceutical, Data Management, Science, Health information management, Debiopharm, Clinical professor, Software, Industry, Mayo Clinic, Adoption, Patient, VC, ESourcing Capability Model, Technology, Government, Union, EHR, Software as a service, Clinical trial, Guest appearance, Bouquet (EP), Associate, Drug development, Partnership, EDC, Efficiency, Data collection, Laika (EHR testing framework), Research, CRO, R, Therapy, EPRO, Health, Map, Medical imaging, Pharmaceutical industry, Maccabi, Amgen

YonaLink, a clinical trial software provider, today announced that is has completed an initial funding round, raising $6 million, to scale global growth and expand its EHR-to-EDC integration platform.

Key Points: 
  • YonaLink, a clinical trial software provider, today announced that is has completed an initial funding round, raising $6 million, to scale global growth and expand its EHR-to-EDC integration platform.
  • Purpose-built to stream and map up-to-date patient data, in real time, YonaLink's SaaS solution exports patient data directly from a clinical site's EHR system and transfers it into clinical research electronic data capture (EDC) systems.
  • YonaLink is bridging the gap between patient care and clinical research, providing the missing link in clinical trial data collection and validation with technology that securely provides true EHR-to-EDC connectivity, without disrupting existing clinical trial workflows, said Iddo Peleg, YonaLinks CEO and co-founder.
  • YonaLink equips research teams with the ability to extract up-to-date patient data from an EHR and stream that data into a clinical trial electronic data capture (EDC) system in real time, reducing clinical trial timelines and costs.

Chung-Ang University Study Reports Hepatic Toxicity from Endocrine Disrupting Chemical Mixtures

Retrieved on: 
Friday, August 5, 2022
Liver, Ministry of Food and Drug Safety, Risk, Combined, Gene, Mouse, Oxidative stress, Hormone, Plastic, Non-alcoholic fatty liver disease, Cosmetics, Urine, Male, EDC, Cirrhosis, Liver injury, DE, Biotransformation, Ministry, BPA, Infection, Chung-Ang University, Hepatitis, Cholesterol, Journal, Immune system, Cell death, Bouquet (EP), Manifest and latent functions and dysfunctions, Perfume, Steatohepatitis, Food

Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans, pharmaceuticals, and cosmetics, are well-known EDCs.

Key Points: 
  • Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans, pharmaceuticals, and cosmetics, are well-known EDCs.
  • Since both BPA and phthalates are structurally similar to steroid hormones that regulate chemical signaling in the body, they are capable of manipulating and disrupting hormonal functions.
  • Studies involving animal models and human urine samples have confirmed the positive correlation between exposure to individual EDCs and abnormal liver function.
  • "Our study tried to change the conventional toxicological approach and we hope it has an enormous impact on regulatory and public health perspectives," says Prof. Pang.

Slope Appoints Clinical Research Veteran Hope Meely as Slope Chief Clinical Officer

Retrieved on: 
Tuesday, July 19, 2022
Supply chain management, Clinical data management, Supply, AstraZeneca, PPD, Inc., Biorepository, Solution, Knowledge, View, Sanofi, Title 21 CFR Part 11, Multimedia, CFR, Industry, Takeda Pharmaceutical Company, Title 21 of the Code of Federal Regulations, Risk, Hope, GlaxoSmithKline, IRTS, Compliance, Clinical trial, Bouquet (EP), Software as a service, SAN, Pharmaceutical industry, Medical imaging, Slope

SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Slope, provider of the first eClinical Supply Chain Management (eCSCM) platform, announced hiring the clinical research leader, Hope Meely, as Chief Clinical Officer. In her new role, Hope will be instrumental in educating the industry on the new eCSCM software as a service (SaaS) category. Hope will help clinical trial sponsors and research sites understand how replacing existing manual and paper-driven clinical supply chain processes with the Slope eCSCM platform will reduce clinical trial risk and costs, improve the productivity of clinical trial collaborators, and increase subject retention.

Key Points: 
  • SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Slope , provider of the first eClinical Supply Chain Management (eCSCM) platform, announced hiring the clinical research leader, Hope Meely, as Chief Clinical Officer.
  • Hope will help clinical trial sponsors and research sites understand how replacing existing manual and paper-driven clinical supply chain processes with the Slope eCSCM platform will reduce clinical trial risk and costs, improve the productivity of clinical trial collaborators, and increase subject retention.
  • Hope has spent the last three years leading clinical operations for early-phase oncology clinical trials at Prelude Therapeutics.
  • The Slope eCSCM platform reduces clinical trial risks, reigns in costs, improves the productivity of clinical trial collaborators, and increases subject retention.

Texas Oncology selects proXimity™ to automate data transfer for clinical trials

Retrieved on: 
Tuesday, May 31, 2022
Proton, Physician, Patient, Proton therapy, Health, Texas Oncology, Clinical trial, Proximity, ECS, FDA, Bouquet (EP), Time, Program, University of North Texas Center for Human Identification, EDC, EMR, Private practice, Cancer, Emergency, Data management, Medical imaging, BC

VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Texas Oncology has selected proXimityas the primary tool to automate the transfer of clinical trial data from the oncology EMR to the electronic data capture (EDC) systems used by biotech, pharmaceutical, and contract research organizations providing clinical trials with Texas Oncology.

Key Points: 
  • VANCOUVER, BC, May 31, 2022 /PRNewswire/ - Texas Oncology has selected proXimityas the primary tool to automate the transfer of clinical trial data from the oncology EMR to the electronic data capture (EDC) systems used by biotech, pharmaceutical, and contract research organizations providing clinical trials with Texas Oncology.
  • Texas Oncology is a leader in cancer research and clinical trials with more than 1500 patients enrolled annually and, on average, 150+ open national trials.
  • Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, Texas Urology Specialists, and Texas Center for Interventional Surgery.
  • Proximity is a tool set designed to automate data transfer between EMRs and EDCs in support of sponsored clinical trials.